IN2014CN00989A - - Google Patents
Info
- Publication number
- IN2014CN00989A IN2014CN00989A IN989CHN2014A IN2014CN00989A IN 2014CN00989 A IN2014CN00989 A IN 2014CN00989A IN 989CHN2014 A IN989CHN2014 A IN 989CHN2014A IN 2014CN00989 A IN2014CN00989 A IN 2014CN00989A
- Authority
- IN
- India
- Prior art keywords
- compounds
- treprostinil
- pah
- prodrugs
- covalent
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 abstract 2
- 229960005032 treprostinil Drugs 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177409 | 2011-08-12 | ||
| EP11195615 | 2011-12-23 | ||
| EP12165508 | 2012-04-25 | ||
| PCT/EP2012/065745 WO2013024052A1 (en) | 2011-08-12 | 2012-08-10 | Carrier-linked treprostinil prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00989A true IN2014CN00989A (de) | 2015-04-10 |
Family
ID=46690494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN989CHN2014 IN2014CN00989A (de) | 2011-08-12 | 2012-08-10 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9561287B2 (de) |
| EP (1) | EP2741781A1 (de) |
| JP (1) | JP6092867B2 (de) |
| KR (1) | KR101997939B1 (de) |
| CN (1) | CN103857413A (de) |
| AU (1) | AU2012296954B2 (de) |
| BR (1) | BR112014003225A2 (de) |
| CA (1) | CA2843883C (de) |
| HK (1) | HK1198359A1 (de) |
| IL (1) | IL230712A (de) |
| IN (1) | IN2014CN00989A (de) |
| MX (1) | MX349950B (de) |
| WO (1) | WO2013024052A1 (de) |
| ZA (1) | ZA201400977B (de) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2741781A1 (de) * | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Trägerverknüpfte treprostinil-prodrugs |
| AU2013254756B2 (en) * | 2012-04-25 | 2017-03-30 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| WO2014086961A1 (en) | 2012-12-07 | 2014-06-12 | Ascendis Pharma A/S | Carrier-linked prostanoid prodrugs |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| ES2927844T3 (es) | 2013-01-11 | 2022-11-11 | Corsair Pharma Inc | Profármacos de treprostinil |
| WO2014160638A1 (en) * | 2013-03-25 | 2014-10-02 | United Therapeutics Corporation | Process of making prostacyclin compounds with linker thiol and pegylated forms |
| EP2991639A4 (de) | 2013-04-30 | 2016-11-30 | United Therapeutics Corp | Pharmazeutische formulierungen mit kontrollierter freisetzung |
| SI3060041T1 (sl) | 2013-10-25 | 2021-04-30 | Insmed Incorporated | Spojine prostaciklina |
| JO3624B1 (ar) * | 2014-05-08 | 2020-08-27 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| ES2908142T3 (es) * | 2014-06-13 | 2022-04-27 | United Therapeutics Corp | Formulaciones de treprostinil |
| JP6561109B2 (ja) * | 2014-07-16 | 2019-08-14 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| EP3904326A1 (de) | 2014-11-18 | 2021-11-03 | Insmed Incorporated | Verfahren zur herstellung von treprostinil und treprostinilderivat-prodrugs |
| TWI540121B (zh) | 2014-12-01 | 2016-07-01 | 臺灣永光化學工業股份有限公司 | 曲前列環素二乙醇胺之合成方法及新穎中間體 |
| EP3226838A1 (de) * | 2014-12-03 | 2017-10-11 | Steadymed Ltd. | Konservierungsmittelfreie treprostinilformulierungen sowie verfahren und vorrichtungen zur verwendung damit |
| US9643911B2 (en) * | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| AU2017205690B2 (en) | 2016-01-08 | 2022-04-28 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with increased NEP stability |
| CA3008017C (en) | 2016-01-08 | 2024-01-02 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| AU2017205694B2 (en) | 2016-01-08 | 2022-05-26 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low NPR-C binding |
| AU2017205688C1 (en) | 2016-01-08 | 2022-03-10 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| US10835578B2 (en) | 2016-01-08 | 2020-11-17 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
| NZ743488A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
| IL317744A (en) | 2016-03-01 | 2025-02-01 | Ascendis Pharma Bone Diseases As | PTH drug agonists |
| EP3484523A1 (de) | 2016-07-13 | 2019-05-22 | Ascendis Pharma A/S | Konjugationsverfahren für trägerstoffverknüpfte prodrugs |
| DK3512495T3 (da) * | 2016-09-15 | 2022-12-05 | Camurus Ab | Formuleringer af prostacyklinanaloger |
| FI3518982T3 (fi) | 2016-09-29 | 2025-02-11 | Ascendis Pharma Bone Diseases As | Säädellysti vapautuvia PTH-yhdisteitä |
| RS64440B1 (sr) | 2016-09-29 | 2023-09-29 | Ascendis Pharma Bone Diseases As | Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem |
| PL3518961T3 (pl) | 2016-09-29 | 2023-08-14 | Ascendis Pharma Bone Diseases A/S | Związki pth o niskim stosunku wartości maksymalnej do minimalnej |
| HRP20230385T1 (hr) | 2016-09-29 | 2023-06-23 | Ascendis Pharma Growth Disorders A/S | Kombinirana terapija sa cnp agonistima s kontroliranim oslobađanjem |
| EP3498283A1 (de) | 2017-12-14 | 2019-06-19 | Ipsol AG | Glycosidische derivate von treprostinil |
| CA3099620A1 (en) | 2018-05-18 | 2019-11-21 | Ascendis Pharma Bone Diseases A/S | Starting dose of pth conjugates |
| EP3856255A1 (de) | 2018-09-26 | 2021-08-04 | Ascendis Pharma A/S | Behandlung von infektionen |
| MX2021003186A (es) | 2018-09-26 | 2021-07-16 | Ascendis Pharma As | Nuevos conjugados de hidrogel. |
| US12594345B2 (en) | 2018-09-26 | 2026-04-07 | Ascendis Pharma A/S | Degradable hyaluronic acid hydrogels |
| TWI856997B (zh) | 2019-01-04 | 2024-10-01 | 丹麥商阿仙帝斯製藥公司 | 模式辨別受體(pattern recognition receptor)促效劑的共軛物 |
| SG11202105833WA (en) | 2019-01-04 | 2021-07-29 | Ascendis Pharma Oncology Div A/S | Minimization of systemic inflammation |
| US20220054476A1 (en) | 2019-01-04 | 2022-02-24 | Ascendis Pharma Oncology Division A/S | Sustained local drug levels for innate immune agonists |
| WO2020141223A1 (en) | 2019-01-04 | 2020-07-09 | Ascendis Pharma A/S | Induction of sustained local inflammation |
| US12403182B2 (en) | 2019-02-11 | 2025-09-02 | Ascendis Pharma Bone Diseases A/S | Liquid pharmaceutical formulations of PTH conjugates |
| EP3923906A1 (de) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Trockene pharmazeutische formulierungen von cnp-konjugaten |
| CN114072136B (zh) | 2019-04-29 | 2024-11-29 | 英斯梅德股份有限公司 | 曲前列素前药的干粉组合物及其使用方法 |
| WO2020254607A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pd properties |
| WO2020254612A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pd properties |
| WO2020254617A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pk properties |
| WO2020254613A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pk properties |
| CA3143278A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Tyrosine kinase inhibitor conjugates |
| TW202114738A (zh) | 2019-06-21 | 2021-04-16 | 丹麥商阿仙帝斯製藥公司 | 抗ctla4結合物 |
| JP2020011957A (ja) * | 2019-07-22 | 2020-01-23 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| CN115003320A (zh) | 2020-01-13 | 2022-09-02 | 阿森迪斯药物骨疾病股份有限公司 | 甲状旁腺功能减退的治疗 |
| AU2021269007A1 (en) | 2020-05-04 | 2022-11-24 | Ascendis Pharma A/S | Hydrogel irradiation |
| US11793780B2 (en) * | 2020-06-09 | 2023-10-24 | United Therapeutics Corporation | Prodrugs of treprosiinil |
| EP4217004A1 (de) | 2020-09-28 | 2023-08-02 | Ascendis Pharma Bone Diseases A/S | Verbesserung des physischen und geistigen wohlbefindens von patienten mit hypoparathyroidismus |
| JP7138685B2 (ja) * | 2020-10-26 | 2022-09-16 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| WO2022194195A1 (zh) * | 2021-03-16 | 2022-09-22 | 江苏恒瑞医药股份有限公司 | 一种曲前列环素衍生物及其用途 |
| EP4404951A1 (de) | 2021-09-22 | 2024-07-31 | Ascendis Pharma Bone Diseases A/S | Langwirkende behandlungen von pth-verbindungen |
| MX2024006698A (es) | 2021-12-13 | 2024-06-19 | Ascendis Pharma Oncology Div A/S | Tratamientos de cancer con agonistas de los receptores tipo toll 7 y 8 (tlr7/8). |
| CA3236278A1 (en) | 2021-12-13 | 2023-06-22 | Kennett Sprogoe | Effective doses of cnp conjugates |
| CN116444377A (zh) * | 2022-01-07 | 2023-07-18 | 广州楷石医药有限公司 | 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途 |
| WO2023227505A1 (en) | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
| CN120752051A (zh) | 2022-11-02 | 2025-10-03 | 阿森迪斯药物骨疾病股份有限公司 | 包含两种pth化合物的pth治疗方案 |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| JP2026510974A (ja) | 2023-03-20 | 2026-04-10 | アセンディス ファーマ グロース ディスオーダーズ エー／エス | 軟骨形成不全症のヒト対象における胸腰椎奇形の治療の方法 |
| IL326658A (en) | 2023-09-04 | 2026-04-01 | Ascendis Pharma Bone Diseases As | PTH treatment in chronic kidney disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| CA1241324A (en) | 1984-03-08 | 1988-08-30 | Paul A. Aristoff | Interphenylene carbacyclin derivatives |
| EP1164846A1 (de) * | 1999-03-31 | 2002-01-02 | United Therapeutics Corporation | Prostaglandinverbindungen, zusammensetzungen und verfahren zur behandlung von peripheren gefässkrankheiten und pulmonaler hypertonie |
| CA2521784C (en) * | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| JP4906514B2 (ja) * | 2003-12-16 | 2012-03-28 | ユナイテッド セラピューティクス コーポレイション | 腎臓機能改善のためのトレプロスチニルの用途 |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| EP1625856A1 (de) | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Hydrogel Polymer Prodroge Konjugate |
| US20080280986A1 (en) | 2007-02-09 | 2008-11-13 | United Therapeutics Corporation | Treprostinil treatment for interstitial lung disease and asthma |
| JP5351889B2 (ja) * | 2007-06-21 | 2013-11-27 | テクニシェ ユニバーシタット ミュンヘン | インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質 |
| HUE054585T2 (hu) | 2008-04-29 | 2021-09-28 | Ascendis Pharma Endocrinology Div A/S | Pegilezett rekombináns humán növekedési hormon vegyületek |
| WO2010014258A2 (en) * | 2008-08-01 | 2010-02-04 | Nektar Therapeutics Al, Corporation | Conjugates having a releasable linkage |
| US8637466B2 (en) * | 2008-08-11 | 2014-01-28 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
| EP2898900B1 (de) * | 2008-09-19 | 2017-11-15 | Nektar Therapeutics | Polymerkonjugate von Ziconotid |
| EP2370068A4 (de) * | 2008-12-10 | 2015-09-23 | Paka Pulmonary Pharmaceuticals Inc | Verfahren und zusammensetzungen zur abgabe von medikamenten an die lunge |
| JP5839597B2 (ja) | 2009-06-08 | 2016-01-06 | アムニクス オペレーティング インコーポレイテッド | グルコース調節ポリペプチド並びにその作成及び使用方法 |
| RU2554854C9 (ru) * | 2009-07-31 | 2017-02-03 | Асцендис Фарма Ас | Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля |
| US20130053405A1 (en) * | 2009-10-06 | 2013-02-28 | Ulrich Hersel | Carrier linked paliperidone prodrugs |
| EP2741781A1 (de) * | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Trägerverknüpfte treprostinil-prodrugs |
-
2012
- 2012-08-10 EP EP12748194.3A patent/EP2741781A1/de not_active Withdrawn
- 2012-08-10 KR KR1020147006343A patent/KR101997939B1/ko not_active Expired - Fee Related
- 2012-08-10 JP JP2014524413A patent/JP6092867B2/ja not_active Expired - Fee Related
- 2012-08-10 HK HK14111870.6A patent/HK1198359A1/xx unknown
- 2012-08-10 CA CA2843883A patent/CA2843883C/en not_active Expired - Fee Related
- 2012-08-10 US US14/238,437 patent/US9561287B2/en active Active
- 2012-08-10 IN IN989CHN2014 patent/IN2014CN00989A/en unknown
- 2012-08-10 CN CN201280049725.9A patent/CN103857413A/zh active Pending
- 2012-08-10 WO PCT/EP2012/065745 patent/WO2013024052A1/en not_active Ceased
- 2012-08-10 AU AU2012296954A patent/AU2012296954B2/en not_active Ceased
- 2012-08-10 BR BR112014003225A patent/BR112014003225A2/pt not_active Application Discontinuation
- 2012-08-10 MX MX2014001497A patent/MX349950B/es active IP Right Grant
-
2014
- 2014-01-29 IL IL230712A patent/IL230712A/en active IP Right Grant
- 2014-02-10 ZA ZA2014/00977A patent/ZA201400977B/en unknown
-
2017
- 2017-01-27 US US15/418,180 patent/US10729778B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140296150A1 (en) | 2014-10-02 |
| WO2013024052A1 (en) | 2013-02-21 |
| JP2014527050A (ja) | 2014-10-09 |
| IL230712A0 (en) | 2014-03-31 |
| CA2843883C (en) | 2020-04-28 |
| AU2012296954A1 (en) | 2014-02-20 |
| KR101997939B1 (ko) | 2019-07-08 |
| US9561287B2 (en) | 2017-02-07 |
| MX349950B (es) | 2017-08-22 |
| ZA201400977B (en) | 2017-11-29 |
| HK1198359A1 (en) | 2015-04-10 |
| US20190105400A1 (en) | 2019-04-11 |
| IL230712A (en) | 2017-08-31 |
| AU2012296954B2 (en) | 2016-09-15 |
| BR112014003225A2 (pt) | 2017-03-01 |
| EP2741781A1 (de) | 2014-06-18 |
| JP6092867B2 (ja) | 2017-03-08 |
| MX2014001497A (es) | 2014-04-25 |
| KR20140070545A (ko) | 2014-06-10 |
| CN103857413A (zh) | 2014-06-11 |
| US10729778B2 (en) | 2020-08-04 |
| CA2843883A1 (en) | 2013-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX349950B (es) | Profarmacos de treprostinil enlazados a un portador. | |
| PH12017501429A1 (en) | Derivatives of betulin | |
| MY187718A (en) | Pharmaceutical formulations | |
| WO2012122340A8 (en) | Soluble guanylate cyclase activators | |
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| MX361653B (es) | Procedimiento para la preparación de derivados del ácido biliar. | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| PH12014502733A1 (en) | Neprilysin inhibitors | |
| MX2014004196A (es) | Citramida de rasagilina. | |
| TN2014000112A1 (en) | Ep1 receptor ligands | |
| IN2012DN02139A (de) | ||
| MY153958A (en) | Lxr modulators | |
| WO2010150211A3 (en) | Use of derivatives of indoles for the treatment of cancer | |
| MX2011011776A (es) | Nuevos profarmacos de triptolite. | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| IN2014CN04449A (de) | ||
| WO2013093931A3 (en) | Novel prodrugs of phenolic drugs | |
| IN2013DN02555A (de) | ||
| MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
| WO2014030173A3 (en) | Improved process for preparation of atazanavir bisulfate | |
| WO2012176163A3 (en) | Compounds for the treatment of cancers associated with human papillomavirus | |
| MX2013002656A (es) | Nuevo proceso. |